PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 45/06, A61P 9/00

A1

(11) International Publication Number: WO 00/38724

(43) International Publication Date: 6 July 2000 (06.07.00)

(21) International Application Number: PCT/US99/27945

(22) International Filing Date: 17 December 1999 (17.12.99)

(30) Priority Data:

60/113,955	23 December 1998 (23.12.98)	US
60/142,616	7 July 1999 (07.07.99)	US

(71) Applicant *(for all designated States except US)*: G.D. SEARLE & CO. [US/US]; Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680–5110 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SIKORSKI, James, A. [US/US]; 2313 East Royal Court, Des Peres, MO 63131 (US). GLENN, Kevin, C. [US/US]; 509 Princeton Gate Court, Chesterfield, MO 63017 (US).

(74) Agents: WARNER, James, M. et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680–5110 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND FIBRIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS

(57) Abstract

The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a fibric acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.